Cynata Therapeutics Overview

  • Founded

  • 2011

Founded
  • Status

  • Public

  • Employees

  • 2

Employees
  • Stock Symbol

  • CYP

Stock Symbol
  • Investments

  • 3

  • Share Price

  • $0.09

  • (As of Monday Closing)

Cynata Therapeutics General Information

Description

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Contact Information

Website
www.cynata.com
Formerly Known As
EcoQuest
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Stock Exchange
ASX
Primary Office
  • PO Box 7165
  • Hawthorn North, Victoria 3122
  • Australia
+61 (03) 0000 0000

Cynata Therapeutics Timeline

2020202120222023
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cynata Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.09 $0.10 $0.09 - $0.32 $16.9M 179M 236K

Cynata Therapeutics Financials Summary

In Thousands,
USD 		TTM 31-Mar-2023 FY 2022 30-Jun-2022 FY 2021 30-Jun-2021 FY 2020 30-Jun-2020
EV 15,776 19,111 34,290 39,713
EBITDA (3,790) (5,593) (2,345)
Net Income (3,946) (5,733) (2,438)
Total Assets 18,263 22,521 12,011
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cynata Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cynata Therapeutics‘s full profile, request access.

Request a free trial

Cynata Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC)
Biotechnology
Hawthorn North, Australia
2 As of 2008
000.00
000000000 000.00

00000

usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim venia
0000 000000000
Haifa, Israel
000 As of 0000
00000
000000000 00000

000000

iusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
0000000000000
Melbourne, Australia
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cynata Therapeutics Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pluri Corporation Haifa, Israel 000 00000 000000000 00000
000000000 Corporation Melbourne, Australia 00 00000 000000000 00000
00000000 Corporation Sydney, Australia 00 00.00 00000000 00.00
00000000 Corporation Cleveland, OH 00 000.00 000000000 000.00
To view Cynata Therapeutics’s complete competitors history, request access »

Cynata Therapeutics Patents

  • 46

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Cynata Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3931308-A4 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019 0000000000 0
EP-3931308-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019 0000000000
US-20220119773-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019 0000000000
AU-2020227617-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019 0000000000
CA-3131395-A1 Method for improving angiogenic potential of a mesenchymal stem cell Pending 28-Feb-2019 C12N5/0691
To view Cynata Therapeutics’s complete patent history, request access »

Cynata Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Ross Macdonald Ph.D Chief Executive Officer & Managing Director
Kilian Kelly Ph.D Chief Operating Officer
Jolanta Airey Chief Medical Officer
To view Cynata Therapeutics’s complete executive team members history, request access »

Cynata Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cynata Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cynata Therapeutics‘s full profile, request access.

Request a free trial

Cynata Therapeutics Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 01-Dec-2013 0000000000 Drug Discovery
000 00000 25-Oct-2013 0000000000 Biotechnology 000000 00
Cynata 17-Sep-2012 Corporate 00000 Drug Discovery
To view Cynata Therapeutics’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Cynata Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Cynata Therapeutics’s complete esg history, request access »